These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25998501)

  • 1. Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists.
    Koura M; Matsuda T; Okuda A; Watanabe Y; Yamaguchi Y; Kurobuchi S; Matsumoto Y; Shibuya K
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2668-74. PubMed ID: 25998501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists.
    Matsuda T; Okuda A; Watanabe Y; Miura T; Ozawa H; Tosaka A; Yamazaki K; Yamaguchi Y; Kurobuchi S; Koura M; Shibuya K
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1274-8. PubMed ID: 25677664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
    Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
    Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.
    Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C
    Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
    Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
    Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in liver X receptor-selective modulators.
    Ratni H; Wright MB
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):403-13. PubMed ID: 20597026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
    Srivastava RA
    Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
    van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
    Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
    Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
    Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver X receptors and atherosclerosis: it is not all cholesterol.
    Ignatova ID; Schulman IG
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):242-3. PubMed ID: 24431422
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.
    Briand O; Touche V; Colin S; Brufau G; Davalos A; Schonewille M; Bovenga F; Carrière V; de Boer JF; Dugardin C; Riveau B; Clavey V; Tailleux A; Moschetta A; Lasunción MA; Groen AK; Staels B; Lestavel S
    Gastroenterology; 2016 Mar; 150(3):650-8. PubMed ID: 26602218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
    Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
    Briand F; Tréguier M; André A; Grillot D; Issandou M; Ouguerram K; Sulpice T
    J Lipid Res; 2010 Apr; 51(4):763-70. PubMed ID: 19965597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.
    Matsui Y; Yamaguchi T; Yamazaki T; Yoshida M; Arai M; Terasaka N; Honzumi S; Wakabayashi K; Hayashi S; Nakai D; Hanzawa H; Tamaki K
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3914-20. PubMed ID: 26238323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.